menu
    • menu
    [{"orgOrder":0,"company":"AmbioPharm","sponsor":"Adalvo","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Peptide","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"AmbioPharm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"AmbioPharm \/ AmbioPharm","highestDevelopmentStatusID":"1","companyTruncated":"AmbioPharm \/ AmbioPharm"},{"orgOrder":0,"company":"AmbioPharm","sponsor":"Upsher-Smith Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Peptide","year":"2020","type":"Partnership","leadProduct":"Corticotropin","moa":"ACTH","graph1":"Neurology","graph2":"Approved","graph3":"AmbioPharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AmbioPharm \/ Upsher-Smith Laboratories","highestDevelopmentStatusID":"12","companyTruncated":"AmbioPharm \/ Upsher-Smith Laboratories"},{"orgOrder":0,"company":"AmbioPharm","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Thrixopelma pruriens venom peptide","moa":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"AmbioPharm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"AmbioPharm \/ AmbioPharm","highestDevelopmentStatusID":"1","companyTruncated":"AmbioPharm \/ AmbioPharm"},{"orgOrder":0,"company":"AmbioPharm","sponsor":"Adalvo","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Approved","graph3":"AmbioPharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"AmbioPharm \/ AmbioPharm","highestDevelopmentStatusID":"12","companyTruncated":"AmbioPharm \/ AmbioPharm"},{"orgOrder":0,"company":"AmbioPharm","sponsor":"ONL Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ONL1204","moa":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"AmbioPharm","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AmbioPharm \/ ONL Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"AmbioPharm \/ ONL Therapeutics"},{"orgOrder":0,"company":"AmbioPharm","sponsor":"Amytrx Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Peptide","year":"2022","type":"Partnership","leadProduct":"AMTX-100","moa":"NF-kB","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"AmbioPharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"AmbioPharm \/ AmbioPharm","highestDevelopmentStatusID":"7","companyTruncated":"AmbioPharm \/ AmbioPharm"},{"orgOrder":0,"company":"AmbioPharm","sponsor":"OKYO Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"OK-101","moa":"ChemR23","graph1":"Ophthalmology","graph2":"Phase II","graph3":"AmbioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"AmbioPharm \/ AmbioPharma","highestDevelopmentStatusID":"8","companyTruncated":"AmbioPharm \/ AmbioPharma"}]

    Find Clinical Drug Pipeline Developments & Deals by AmbioPharm

    Menu

    AmbioPharm

    EVENTS

    • Webinars & Exhibitions

    VIDEO(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AmbioPharm

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            AmbioPharm

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OK-101

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Recipient : OKYO Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to Treat Dry Eye Disease with Subsequent Phase 2 Initiation Alo...

                            Details : The OK-101 drug candidate displays potent anti-inflammatory activity in animal models of DED. OK-101 also reduces Corneal Neuropathic Pain (CNP) in a ciliary nerve ligation animal model of CNP.

                            Brand Name : OK-101

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 30, 2022

                            Lead Product(s) : OK-101

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Recipient : OKYO Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AmbioPharm

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            AmbioPharm

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMTX-100

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I/ Phase II

                            Recipient : Amytrx Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Amytrx Therapeutics Partners With AmbioPharm to Expand the Potential of Its Breakthrough Leukocyte-Targeting A...

                            Details : Amytrx has identified new opportunities for other inflammatory and metabolic diseases with attractive out-licensing and collaborative opportunities using its proprietary AMTX-100 human peptide platform.

                            Brand Name : AMTX-100

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            July 26, 2022

                            Lead Product(s) : AMTX-100

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Amytrx Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AmbioPharm

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            AmbioPharm

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ONL1204

                            Therapeutic Area : Ophthalmology

                            Study Phase : IND Enabling

                            Sponsor : ONL Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AmbioPharm Supports ONL Therapeutics with Peptide Manufacturing to Prepare for IND Application for Phase 2 Stu...

                            Details : ONL1204 Ophthalmic Solution is a novel, first-in-class small peptide Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs in a range of retinal diseases and conditions.

                            Brand Name : ONL1204

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 12, 2022

                            Lead Product(s) : ONL1204

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : IND Enabling

                            Sponsor : ONL Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AmbioPharm

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            AmbioPharm

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Icatibant Acetate

                            Therapeutic Area : Genetic Disease

                            Study Phase : Approved

                            Recipient : Adalvo

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Adalvo Announces Successful DCP Closure for Icatibant

                            Details : Icatibant, a complex injectable peptide product, forming part of high-value product, is an equivalent and more affordable version of Firazyr (Takeda/Shire), used used to treat a serious orphan disease, acute attacks of hereditary angioedema.

                            Brand Name : Icatibant Acetate-Generic

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            September 28, 2021

                            Lead Product(s) : Icatibant Acetate

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Approved

                            Recipient : Adalvo

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            AmbioPharm

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            AmbioPharm

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Thrixopelma pruriens venom peptide

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Recipient : University of California

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AmbioPharm Inc. Working with University of California Davis to Develop Non-Opioid Peptide-Based Pain Therapeut...

                            Details : Researchers have utilized a venom peptide originally isolated from the Peruvian green velvet tarantula (Thrixopelma pruriens) that blocks Nav1.7 voltage-gated ion channels, an ion channel important in pain signaling.

                            Brand Name : Undisclosed

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            July 20, 2021

                            Lead Product(s) : Thrixopelma pruriens venom peptide

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Recipient : University of California

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            AmbioPharm

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            AmbioPharm

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Corticotropin

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Upsher-Smith Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Upsher-Smith and AmbioPharm Announce Partnership Agreement to Develop and Market Corticotropin Injection

                            Details : AmbioPharm will manufacture the active pharmaceutical ingredient exclusively for Upsher-Smith. A contract manufacturing organization will exclusively supply Upsher-Smith with the finished product for sale in the United States.

                            Brand Name : Acthar

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            August 07, 2020

                            Lead Product(s) : Corticotropin

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Upsher-Smith Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            AmbioPharm

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            AmbioPharm

                            U.S.A arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Study Phase : Undisclosed

                            Recipient : Adalvo

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Adalvo and AmbioPharm Partner on Development & Licensing for Key Peptide Product

                            Details : The partnership includes a basket of difficult-to-make peptide products that will be used to treat various diseases, ranging from diabetes to immunology disorders, cardiologic and endocrinology diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            July 29, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Undisclosed

                            Recipient : Adalvo

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth